• ISBN13: 9788126941438
• Binding: Hardcover
• Subject: Medical, Nursing and Health Sciences
• Publisher: Atlantic Publishers & Distributors (P) Ltd
• Publisher Imprint: Atlantic
• Publication Date: July 11, 2025
• Pages: 253
• Original Price: INR 895.0
• Language: English
• Edition: N/A
• Item Weight: 500 grams
• BISAC Subject(s): Industries / Pharmaceutical & Biotechnology, Nursing / Pharmacology, and Pharmaceutical

Indian Pharma 2030: Global Leadership with Foresight examines India’s pharmaceutical sector, tracing its evolution, growth in the last decade and future potential. It covers regulatory frameworks, global harmonisation efforts, and emerging trends like biosimilars, APIs and lifestyle disease treatments. The book outlines strategies for achieving pharmaceutical leadership by 2030, including increased generic medicine adoption, biosimilar market expansion and CDMO opportunities. Highlighting India’s vision, the book emphasises integration with international regulatory systems and innovation-driven R&D, presenting a roadmap for global leadership in pharmaceuticals.

Dr Aseem Chauhan, a Wharton alumnus and Chancellor at Amity University, is a Founding Trustee of the Amity Education Group. As Founder and CEO of the Amity Innovation Incubator, he has played a key role in establishing the university's global presence. He has co-authored VUCA in Start-Ups and various articles on VUCA.

Suhayl Abidi, an MBA from FMS Delhi and a PG Diploma in Information Management from Leeds Polytechnic, UK, is a consultant at the Centre for VUCA Studies, Amity University. With over 25 years of corporate experience at Reliance Industries, Essar and the Piramal Group, he brings hands-on expertise in organisational learning and knowledge management. He has co-authored The VUCA Company, The VUCA Learner, VUCA in Start-Ups, and several articles on the VUCA paradigm.

Prof Dr Manoj Joshi, PhD in Strategy, is a seasoned professor specialising in strategy, innovation and entrepreneurship. He leads the Centre for VUCA Studies at Amity University and has over 33 years of combined academic and industry experience. A prolific author with 4 books and over 200 articles on VUCA to his credit, he also serves as an editor, columnist and visiting professor at various reputed institutions.

Prof Dr Ashok Kumar is PhD with professional qualifications in Business Management and Demography. He has also received advanced management training from Ashorne Hill College of Management, UK. A senior consultant at Amity University's Centre for VUCA Studies, he brings over five decades of academic and industry experience. He has co-authored VUCA in Start-Ups and several scholarly articles on the subject.

• Advance Praise........................................................ iii
• Foreword................................................................. xiii
• Preface..................................................................... xv
• Acknowledgements.................................................. xvii
• Abbreviations and Acronyms................................... xix
• 1. Introduction............................................................. 1
1.1 Convergence of Events Favouring Pharma
• Industry 4
• References 15
2. India Pharmaceutical Sector..................................... 17
• 2.1 Evolution of the Indian Pharmaceutical Sector 17
• 2.2 Pharmaceutical Sector Growth in the Last Decade 2010–2020 17
• 2.3 India Pharma Vision 2020 and 2047 21
• 2.4 Growth of Lifestyle Diseases in India 22
• 2.5 Indian Biosimilar Market 22
• 2.6 Indian Pharmaceutical Exports 25
• 2.7 API-Active Pharmaceutical Intermediates 42
• 2.8 Increase Profitability of Janaushadhi Stores 58
• References 60
3. Anticipatory Regulatory Environment for
• Leveraging Opportunities........................................ 65
• 3.1 Quality Manufacturing Rankings 67
• 3.2 Global Harmonisation Movements 68
• 3.3 African Drug Harmonisation Initiative 69
• 3.4 Global Harmonisation Initiatives 71
• 3.5 Pharmaceutical Inspection Co-operation Scheme (PIC/S) 71
• 3.6 European Union 76
• 3.7 United States 78
• References 83
4. Future Growth Opportunities Towards 2030......... 85
• 4.1 Increase Intake of Generic Medicines in European Countries 85
• 4.2 Gain Higher Market Share in Biosimilars 92
• 4.3 CDMOs (Contract Development and Manufacturing Organisations) 105
• 4.4 Novel Drug Development 113
• 4.5 Outsourcing of Packaging 118
• 4.6 Rise of GCC (Global Capability Centres) in India 119
• 4.7 Cutting Drug Development Costs 120
• 4.8 Information Technology to Cut Drug Discovery
• and Development Costs 121
• 4.9 Cooperative Efforts with Other Countries 122
• 4.10 Plant-based Health Products 125
• 4.11 Phytochemicals 133
• 4.12 Drugs Off-patent but No Generic in the Market 138
• 4.13 New Guidance on CGTs to Improve Generic
• Competitiveness 140
• 4.14 Overseas Manufacturing in Our Export Markets 141
• 4.15 Competition from Bangladesh 156
• 4.16 Move Production of Common Drugs Overseas 157
• 4.17 Develop the World’s No. 1 API Industry 158
• References 177
5. The VUCA Scenarios for Global Leadership........... 185
• 5.1 Take Common Generic Manufacturing to Africa 196
• 5.2 An Integrated Manufacturing and Service Strategy 204
• 5.3 Build Manufacturing Zones in Select Global Hubs 207
• 5.4 A Fresh Look at Africa 214
• 5.5 Integration with International Regulatory Systems 216
• 5.6 Complex Generic and Bio-generic Manufacturing within the Country 217
• 5.7 CDMO—The Big Growth Area 217
• 5.8 Strive to be No. 1 in API Manufacturing 218
• 5.9 R&D-based Pharmaceutical Development 219
• References 220
• Index 223